VaibhavAgrawalMDMBA, MJ, MSHA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center

Request Appointment

Overview of Dr. Agrawal

Dr. Vaibhav Agrawal, based in Duarte, CA, specializes in Hematology with subspecialties in Hematologic Oncology and Myeloproliferative Disorder Hematology-Oncology. He completed his Hematology Fellowship in 2021 at Stanford Health Care and holds an MD from Chicago Medical School. His employment history includes Research Associate at Helford Clinical Research Hospital and Assistant Clinical Professor at City of Hope, along with fellowships at Stanford University School of Medicine and Indiana University Health University Hospital. His experience covers immunotherapy, hematologic oncology, hematopoietic stem cell transplantation, bone marrow transplantation, and acute myeloid leukemia. Dr. Agrawal has several publications on topics relating to his field.

Office
1500 E. Duarte Road
Duarte, CA 91010
Book by Phone+1(667) 213-1957

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2021
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2017 - 2020
Geisinger Health SystemResidency, Internal Medicine/Pediatrics, 2013 - 2017
Loyola University Chicago School of LawM.J., Health Care Law, 2011 - 2015
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2013, MD
Loyola University ChicagoM.B.A., Healthcare Management, 2009 - 2011
Rosalind Franklin University College of Health ProfessionsM.S., Health Care Administration, 2008 - 2011

Certifications & Licensure

CA State Medical License 2020 - 2026
IL State Medical License 2024 - 2026
IN State Medical License 2018 - 2021
PA State Medical License 2013 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Start of enrollment: 2024 Aug 30
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Start of enrollment: 2020 May 04
Recruiting
Phase 1
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients Start of enrollment: 2021 Jan 04
Recruiting
Phase 1, Phase 2

Publications & Presentations

PubMed

27 citations
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
Maxim Norkin, Bronwen E. Shaw, Ruta Brazauskas, Heather R. Tecca, Helen Leather
Biology of Blood and Marrow Transplantation. 2019-02-01
6 citations
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Phila...
Ibrahim Aldoss, Michelle Afkhami, Dongyun Yang, Zhaohui Gu, Sally Mokhtari
American Journal of Hematology. 2023-06-01
39 citations
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Annie Im, Armin Rashidi, Tao Wang, Michael T. Hemmer, Margaret L. MacMillan
Biology of Blood and Marrow Transplantation. 2019-03-01

Lectures

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018